

ITL Granted Important US Patent

ITL Limited (“ITL” or “the Company”), the diversified healthcare company, is pleased to announce that ITL BioMedical’s bacterial detection technology has been granted its 3rd US Patent (“patent”).

ITL BioMedical, one of three divisions within ITL, has been successfully selling a platform of products in the US and UK based around bacterial detection technology for many years and this patent will ensure ITL remains a leading innovator in this space.

ITL BioMedical’s products are distributed in the US by industry leaders Fenwal and in the UK by market leaders BioMerieux. The company has experienced increased demand across many markets such as New Zealand via the NZ Red Cross and in Taiwan where the product has recently been approved for sale by the Taiwanese FDA.

The patent strengthens the intellectual property protection around one of ITL’s key products in the bacterial detection market and adds to ITL’s constantly growing intellectual property portfolio. ITL will lodge around 5 new provisional patents directly in the US this year.

Bill Mobbs, Chairman of ITL commented “This third patent shows that ITL continues to look ahead, be innovative and lead the market in this space. We look forward to announcing further patent awards through the year.”

Enquiries:

Bill Mobbs
Executive Chairman

Ben Knowles
Walbrook Investor Relations
T: +61 (0) 426 277 760
E: ben.knowles@walbrookir.com.au

ITL Limited ABN 16 088 212 088

**Unit 1, 63 Wells Road
Chelsea Heights, Victoria, 3196**

ITL is a diversified healthcare company that specialises in innovative medical devices and procedure packs for global healthcare markets. ITL manufactures in Australia and Malaysia, and has sales offices around the world. In 2015 ITL acquired MyHealthTest (“MHT”), the direct to consumer pathology test provider.

ITL’s patented medical devices have a presence in over 50 countries and protect healthcare workers in millions of procedures annually. ITL supplies its range of customised medical procedure packs to over 200 hospitals across Australia.

Australian Securities Exchange

Code: ITD

Ordinary Shares

94,678,177

Board of Directors

Bill Mobbs	Executive Chairman
Mark Peatey	Non-executive Director
Andrew Turnbull	Non-executive Director

Trevor Doolan	Company Secretary
David Holden	Chief Financial Officer

ITL Contact

Trevor Doolan	Company Secretary
Phone:	+61 3 8773 3050
Email:	info@itl-limited.com

www.itl-limited.com

Media

Ben Knowles	Walbrook IR
Phone:	+61 426 277 760
Email:	ben.knowles@walbrookir.com.au